中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future

文献类型：期刊论文

作者Cheng, Zhongquan2,3; Du, Yang3,4; Yu, Leyi2; Yuan, Zhu2; Tian, Jie1,3,4,5
刊名MOLECULAR IMAGING AND BIOLOGY
出版日期2022-01-31
页码16
关键词Noninvasive imaging Immune checkpoint inhibitor Combined immunotherapy Breast cancer
ISSN号1536-1632
DOI10.1007/s11307-021-01688-9
通讯作者Du, Yang(yang.du@ia.ac.cn) ; Tian, Jie(tian@ieee.org)
英文摘要With the application of mono-immunotherapy in cancer, particularly immune checkpoint inhibitors, improved outcomes have been achieved. However, there are several limitations to immunotherapy, such as a poor response to the drugs, immune resistance, and immune-related adverse events. In recent years, studies of preclinical animal models and clinical trials have demonstrated that immune checkpoint inhibitors for breast cancer can significantly prolong the overall survival and quality of patients' lives. Meanwhile, combined immune checkpoint inhibitor treatment has attracted researchers' attention and showed great potential in the comprehensive treatment of breast cancer patients. Additionally, noninvasive imaging enables physicians to predict response to combined immunotherapeutic drugs, achieve treatment efficacy, and lead to better clinical management. Herein, we review the background of combined immune checkpoint inhibitor therapy and summarize its targeted imaging as well as progress in noninvasive imaging aimed at evaluating therapeutic outcomes. Finally, we describe several factors that may influence the outcome of this combined immunotherapy, the future direction of medical imaging, and the potential application of artificial intelligence in breast cancer. With further development of noninvasive imaging for the guidance of combined immune checkpoint inhibitors, cures for this disease may be achieved.
WOS关键词NEOADJUVANT CHEMOTHERAPY ; ADJUVANT IMMUNOTHERAPY ; COMBINATION ; BLOCKADE ; THERAPY ; CHALLENGES ; BIOMARKERS ; EFFICACY ; CTLA-4 ; TRASTUZUMAB
资助项目Beijing Natural Science Foundation[7212207] ; National Natural Science Foundation of China[62027901] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[91859119] ; National Natural Science Foundation of China[61671449] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61901472] ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences[2018PT32003] ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences[2017PT32004] ; National Key R&D Program of China[2018YFC0910602] ; National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFA0700401] ; National Key R&D Program of China[2016YFA0100902] ; National Key R&D Program of China[2016YFC0103702] ; natural science foundation of beijing municipality[62027901] ; natural science foundation of beijing municipality[81871514] ; natural science foundation of beijing municipality[81227901] ; natural science foundation of beijing municipality[81470083] ; natural science foundation of beijing municipality[91859119] ; natural science foundation of beijing municipality[61671449] ; natural science foundation of beijing municipality[81527805] ; natural science foundation of beijing municipality[61901472]
WOS研究方向Radiology, Nuclear Medicine & Medical Imaging
语种英语
WOS记录号WOS:000750274000001
出版者SPRINGER
资助机构Beijing Natural Science Foundation ; National Natural Science Foundation of China ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences ; National Key R&D Program of China ; natural science foundation of beijing municipality
源URL[http://ir.ia.ac.cn/handle/173211/47367]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Du, Yang; Tian, Jie
作者单位1.Xidian Univ, Sch Life Sci & Technol, Xian 710071, Shaanxi, Peoples R China
2.Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China
3.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Key Lab Mol Imaging,State Key Lab Management & Co, Beijing 100190, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
5.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med Sci & Engn, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714		 Cheng, Zhongquan,Du, Yang,Yu, Leyi,et al. Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future[J]. MOLECULAR IMAGING AND BIOLOGY,2022:16.
APA Cheng, Zhongquan,Du, Yang,Yu, Leyi,Yuan, Zhu,&Tian, Jie.(2022).Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.MOLECULAR IMAGING AND BIOLOGY,16.
MLA Cheng, Zhongquan,et al."Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future".MOLECULAR IMAGING AND BIOLOGY (2022):16.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。